Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-017247
Filing Date
2022-08-15
Accepted
2022-08-15 08:16:57
Documents
73
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tals-20220630.htm   iXBRL 10-Q 3442779
2 EX-31.1 tals-ex31_1.htm EX-31.1 17960
3 EX-31.2 tals-ex31_2.htm EX-31.2 17985
4 EX-32.1 tals-ex32_1.htm EX-32.1 10744
5 EX-32.2 tals-ex32_2.htm EX-32.2 11034
  Complete submission text file 0000950170-22-017247.txt   10167493

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tals-20220630_def.xml EX-101.DEF 232130
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tals-20220630_lab.xml EX-101.LAB 462104
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tals-20220630_cal.xml EX-101.CAL 39962
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tals-20220630.xsd EX-101.SCH 52268
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tals-20220630_pre.xml EX-101.PRE 354762
67 EXTRACTED XBRL INSTANCE DOCUMENT tals-20220630_htm.xml XML 1747140
Mailing Address 93 WORCESTER STREET WELLESLEY MA 02481
Business Address 570 PRESTON ST. SUITE 400 LOUISVILLE KY 40202 502-398-9250
Talaris Therapeutics, Inc. (Filer) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40384 | Film No.: 221162496
SIC: 2836 Biological Products, (No Diagnostic Substances)